Cogentix Medical, Inc. (NASDAQ:CGNT) has earned an average broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy recommendation.
Brokerages have set a 1 year consensus target price of $4.58 for the company, according to Zacks. Zacks has also given Cogentix Medical an industry rank of 163 out of 265 based on the ratings given to its competitors.
A number of brokerages recently commented on CGNT. Zacks Investment Research downgraded shares of Cogentix Medical from a “buy” rating to a “hold” rating in a report on Wednesday, December 20th. Aegis began coverage on shares of Cogentix Medical in a report on Friday, December 1st. They issued a “buy” rating and a $4.75 price target for the company. TheStreet raised shares of Cogentix Medical from a “d+” rating to a “c” rating in a report on Thursday, November 9th. Roth Capital began coverage on shares of Cogentix Medical in a report on Wednesday, November 8th. They issued a “buy” rating and a $4.00 price target for the company. Finally, JMP Securities began coverage on shares of Cogentix Medical in a report on Friday, October 6th. They issued an “outperform” rating and a $5.00 price target for the company.
Several large investors have recently made changes to their positions in CGNT. Broadfin Capital LLC lifted its stake in Cogentix Medical by 45.2% in the second quarter. Broadfin Capital LLC now owns 1,094,544 shares of the medical device company’s stock worth $1,905,000 after purchasing an additional 340,771 shares during the last quarter. Dimensional Fund Advisors LP bought a new stake in Cogentix Medical in the third quarter worth about $152,000. Finally, Northern Trust Corp lifted its stake in Cogentix Medical by 0.4% in the second quarter. Northern Trust Corp now owns 73,926 shares of the medical device company’s stock worth $129,000 after purchasing an additional 326 shares during the last quarter. 13.31% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This report was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this report can be viewed at https://stocknewstimes.com/2018/01/17/zacks-cogentix-medical-inc-cgnt-given-4-58-consensus-target-price-by-analysts.html.
About Cogentix Medical
Cogentix Medical, Inc is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cogentix Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogentix Medical and related companies with MarketBeat.com's FREE daily email newsletter.